Hultman C Scott, McPhail Lindsee E, Donaldson Jeffrey H, Wohl David A
Division of Plastic and Reconstructive Surgery, University of North Carolina, Chapel Hill, North Carolina 27599-7195, USA.
Ann Plast Surg. 2007 Mar;58(3):255-63. doi: 10.1097/01.sap.0000248128.33465.83.
HIV-associated lipodystrophy is a frequent consequence of highly active antiretroviral therapy and has been associated with several metabolic disorders (increased triglycerides, hypercholesterolemia, insulin resistance) as well as altered fat distribution, including lipohypertrophy (neck, trunk, breasts) and lipoatrophy (nasolabial fold, cheek, extremities). Medical treatment of fat redistribution is usually ineffective. We evaluated the efficacy and safety of the surgical management of HIV lipodystrophy.
We performed a retrospective review of 12 consecutive patients (3 female, 9 male; mean age, 44.4 years; mean CD4+ cell count, 554/mm3; mean body mass index, 28.9 kg/m2; mean triglycerides, 421 mg/dL; no active opportunistic infections; mean duration of HIV infection, 11.4 years) who underwent surgical management of HIV lipodystrophy at a university hospital from 2001 to 2006.
Surgical intervention included a combination of ultrasonic-assisted liposuction (UAL) and suction-assisted lipectomy (SAL) of the anterior neck (7 patients), posterior neck (10 patients), and trunk (2 patients); direct excision of mastoid fat pads (1 patient); direct excision of thigh lipomata (1 patient); facelift/necklift (1 patient); browlift (1 patient); fat injections (1 patient); and blepharoplasty (2 patients). Mean lipoaspirate volume was 701 mL (range, 270-1400 mL). Complications and sequelae included seroma (1 patient), ecchymosis (1 patient), need for revision (2 patients), and recurrence (3 patients) but did not include nerve injury, fat necrosis, skin loss, or infection. Although all patients reported improvement in form and function, UAL/SAL of the anterior neck had limited efficacy in 3 of 7 patients. UAL/SAL of the cervicodorsal fat pad was initially successful in 10 of 10 patients, but 3 patients developed partial late (>1 year) recurrence, all associated with weight gain. Mean follow up was 30 months (range, 1-66 months).
Despite the potential for recurrence, surgical management of HIV-associated lipodystrophy is efficacious with minimal morbidity. UAL/SAL is particularly beneficial in reducing the cervicodorsal fat pad, whereas facelift and necklift may be necessary to adequately address anterior neck lipohypertrophy.
HIV相关脂肪代谢障碍是高效抗逆转录病毒治疗的常见后果,与多种代谢紊乱(甘油三酯升高、高胆固醇血症、胰岛素抵抗)以及脂肪分布改变有关,包括脂肪增多(颈部、躯干、乳房)和脂肪萎缩(鼻唇沟、脸颊、四肢)。脂肪重新分布的药物治疗通常无效。我们评估了HIV脂肪代谢障碍手术治疗的疗效和安全性。
我们对2001年至2006年在一家大学医院接受HIV脂肪代谢障碍手术治疗的12例连续患者(3例女性,9例男性;平均年龄44.4岁;平均CD4 +细胞计数554/mm³;平均体重指数28.9 kg/m²;平均甘油三酯421 mg/dL;无活动性机会性感染;平均HIV感染持续时间11.4年)进行了回顾性研究。
手术干预包括超声辅助吸脂术(UAL)和前颈部(7例)、后颈部(10例)及躯干(2例)的吸脂辅助脂肪切除术(SAL)联合应用;乳突脂肪垫直接切除术(1例);大腿脂肪瘤直接切除术(1例);面部提升/颈部提升术(1例);眉提升术(1例);脂肪注射(1例);以及眼睑成形术(2例)。平均吸脂量为701 mL(范围270 - 1400 mL)。并发症和后遗症包括血清肿(1例)、瘀斑(1例)、需要修复(2例)和复发(3例),但不包括神经损伤、脂肪坏死、皮肤缺失或感染。尽管所有患者均报告外形和功能有所改善,但前颈部的UAL/SAL在7例患者中有3例疗效有限。颈背部脂肪垫的UAL/SAL最初在10例患者中有10例成功,但3例患者出现部分晚期(>1年)复发,均与体重增加有关。平均随访30个月(范围1 - 66个月)。
尽管存在复发的可能性,但HIV相关脂肪代谢障碍的手术治疗是有效的,且发病率极低。UAL/SAL在减少颈背部脂肪垫方面特别有益,而面部提升和颈部提升可能是充分解决前颈部脂肪增多所必需的。